Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Vivmark Residential Common Shares of Beneficial Interest (VMRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Vivmark Residential Common Shares of Beneficial Interest — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Vivmark Residential Common Shares of Beneficial Interest trades at $61.44 (market cap $47.36B). The key difference: Vivmark Residential Common Shares of Beneficial Interest is far larger — about 5.6× Hinge Health Inc. Class A Common Stock's market cap, and Vivmark Residential Common Shares of Beneficial Interest pays a 4.59% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Vivmark Residential Common Shares of Beneficial Interest for 6 Days on average.
| HNGE | VMRK | |
|---|---|---|
Market Cap | $8.48B | $47.36B |
Volume | 879,799 | 4,011,655 |
Sector | Health | Real Estate |
52-Week High | $105.14 | $70.15 |
52-Week Low | $31.17 | $57.98 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $8.10B | $56.46B |
Dividend Yield | — | 4.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
VMRK trades at $61.2, down 0.08% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $3.04B and net income of $1.05B for 2025, but recent quarterly EPS misses and a slight decline in 2026 profit margins highlight near-term challenges. Recent news includes institutional buying and a credit rating upgrade to 'A' by S&P Global Ratings on August 18, 2026.
The outlook is mixed: analyst consensus is a buy with a $71.67 price target, but technical weakness and earnings misses pose risks. Opportunities include strong profitability and institutional support, while risks involve execution post-merger and market volatility. The stock's valuation metrics suggest it is fairly priced relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Vivmark Residential Common Shares of Beneficial Interest
Vivmark Residential is a residential real estate investment trust that owns and operates apartment communities in U.S. markets. Its portfolio includes apartment homes and development projects.
Read more on VMRK →
